GLP-1r receptor agonist compound salt and crystal form thereof, preparation method therefor and use thereof
Patent Information
- Application Number
- MYPI2025006391
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-21
- Filing Date
- 2024-04-19
- Publication Date
- 2024-10-21
AI Technical Summary
Existing GLP-1R receptor agonist compounds have few solid forms and poor stability, resulting in poor stability at room temperature or high temperature. The solid properties of the compounds are not ideal and are difficult to process.
Provided is a crystal form of a GLP-1R receptor agonist compound salt and a preparation method thereof. By forming a salt with 2-amino-2-(hydroxymethyl)-1,3-propanediol salt or a solvate thereof, the compound can be improved stability and medicinal prospects, including the preparation and application of different crystal forms.
The stability of GLP-1R receptor agonist compounds has been improved, with excellent solid properties, stable under pressure, grinding and high humidity conditions, and has good medicinal prospects.
Smart Images

Figure PI2025006391_DRAWING_001 
Figure PI2025006391_DRAWING_002 
Figure PI2025006391_DRAWING_003
Abstract
Description
A GLP-1R receptor agonist compound salt, its crystal form, its preparation method and application
[0001] This application claims the benefit of Chinese patent application No. 2023104355011, filed on April 21, 2023. This application incorporates the entirety of the aforementioned Chinese patent application. Technical Field
[0002] The present invention relates to a GLP-1R receptor agonist compound salt, a crystal form thereof, a preparation method and an application thereof, and particularly relates to 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate, a preparation method and an application thereof. Background Art
[0003] (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid is a GLP-1R agonist used to treat metabolic-related diseases such as diabetes, obesity, non-alcoholic fatty liver disease, and hypertension.
[0004] Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone that stimulates insulin release. It binds to and activates the GLP-1 receptor (GLP-1R) of the class B family of G protein-coupled receptors (GPCRs) to exert its regulatory function. GLP-1 receptor agonists (GLP-1RAs) are synthetic drugs designed to mimic the physiological functions of GLP-1. After binding to the GLP-1R in pancreatic cells, they stimulate insulin synthesis and secretion in a glucose-dependent manner; reduce glucagon release; act on GLP-1R in the central nervous system, thereby reducing food intake; increase energy expenditure by promoting thermogenesis in brown adipose tissue and decomposition in white adipose tissue; and delay gastric emptying. GLP-1RAs are clinically indicated for adult patients with type 2 diabetes (T2DM) and have significant glucose-lowering effects, while also reducing weight, systolic blood pressure, and improving dyslipidemia. GLP-1RAs can be used alone or in combination with other glucose-lowering agents. The results of multiple clinical studies have shown that the addition of GLP-1RA is effective after the failure of an oral hypoglycemic drug (metformin, sulfonylurea).
[0005] In Example 3 of Chinese patent CN202110334388 filed on March 29, 2021, a compound of formula I was prepared, and the structure of the compound of formula I is as follows:
[0006] Among them, the compound of formula I is (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid, and the preparation method of the compound of formula I is prepared by Example 3 of CN202110334388.
[0007] Formula I compound is used to treat metabolism-related diseases.Described metabolism-related diseases are selected from glucose intolerance, hyperglycemia, dyslipidemia, type 1 diabetes (T1DM), type 2 diabetes (T2DM), hypertriglyceridemia, insulin resistance, impaired glucose tolerance (IGT), diabetic dyslipidemia, hyperlipidemia, arteriosclerosis, any one in the diseases such as atherosclerosis, hypertension, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, cirrhosis, lethargy.But Formula I compound is at room temperature or high temperature condition, and stability is not good, and compound solid property is undesirable, as compound grinding, under pressurization or mixing conditions, compound stability and crystal formation are all easily changed.Therefore, it is urgent to improve compound property by new mode, improve compound stability and pharmaceutics processability, for the application of subsequent compound lays a solid foundation.
[0008] Summary of the Invention
[0009] The technical problem to be solved by the present invention is that existing GLP-1R receptor agonist compounds have limited solid forms and poor stability. To this end, the present invention provides a GLP-1R receptor agonist compound salt, its crystal form, its preparation method, and its use. The salt provided by the present invention has good crystal stability and has promising pharmaceutical prospects.
[0010] The present invention provides a 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of a compound of formula I or a solvate thereof (solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of a compound of formula I);
[0011] In some embodiments, the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I is a compound of formula II,
[0012] In some embodiments, in the solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of Formula I, the solvent is water or 1,4-dioxane; in the solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of Formula I, the molar ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of Formula I to the solvent is preferably 1:(1-0.5), for example, the molar ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of Formula I to the water is 1:1, and for another example, the molar ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of Formula I to the 1,4-dioxane is 1:0.5.
[0013] The present invention provides a crystalline form A of a monohydrate of a compound of formula II, which has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at diffraction peaks at 4.1±0.2°, 8.2±0.2°, 10.7±0.2°, 12.3±0.2° and 20.7±0.2°;
[0014] The structure of the monohydrate of the compound of formula II is:
[0015] Preferably, the single crystal of the monohydrate of the compound of formula II is orthorhombic.
[0016] In some embodiments, the crystalline form A of the monohydrate of the compound of formula II further has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at one or more of the following diffraction peaks: 14.1±0.2°, 14.9±0.2°, 20.5±0.2° and 21.8±0.2°.
[0017] In some embodiments, the crystalline form A of the monohydrate of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 4.1±0.2°, 8.2±0.2°, 10.7±0.2°, 12.3±0.2°, 14.1±0.2°, 14.9±0.2°, 20.5±0.2° and 21.8±0.2°.
[0018] In some embodiments, the crystalline form A of the monohydrate of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles having diffraction peaks as shown in Table 1:
[0019] Table 1
[0020] In some embodiments, the crystalline form A of the monohydrate of the compound of Formula II has an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG1 using Cu-Kα radiation.
[0021] In some embodiments, the differential scanning calorimetry (DSC) curve of Form A of the monohydrate of the compound of Formula II has endothermic peaks at 129.98±3°C and 196.25±3°C.
[0022] In some embodiments, the differential scanning calorimetry curve of Form A of the monohydrate of the compound of Formula II is shown in FIG2 .
[0023] In some embodiments, the thermogravimetric analysis (TGA) curve of Form A of the monohydrate of the compound of Formula II shows a weight loss of 2.468% in the temperature range of 30°C±3°C to 135°C±3°C.
[0024] In some embodiments, the thermogravimetric analysis curve of Form A of the monohydrate of the compound of Formula II is shown in FIG3 .
[0025] In some embodiments, the present invention provides a single crystal of the monohydrate of the compound of formula II having the following unit cell parameters: space group P212121; α=90°, β=90°, γ=90°, The number of asymmetric units in the unit cell is Z = 4, and the crystal density is 1.379 mg / m 3 ;
[0026] Wherein, the structure of the monohydrate of the compound of formula II is:
[0027] Preferably, the single crystal of the monohydrate of the compound of formula II is orthorhombic.
[0028] The present invention provides a crystalline form B of a 1,4-dioxane solvate of a compound of formula II, which has diffraction peaks at 3.4±0.2°, 7.4±0.2°, 11.2±0.2° and 14.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation;
[0029] The structure of the 1,4-dioxane solvate of the compound of formula II is:
[0030] In some embodiments, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II further has an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation and has diffraction peaks at one or more of the following positions: 8.2±0.2°, 12.3±0.2°, 13.7±0.2°, 16.1±0.2°, 20.0±0.2°, 22.0±0.2°, 22.5±0.2° and 29.3±0.2°.
[0031] In some embodiments, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.4±0.2°, 7.4±0.2°, 8.2±0.2°, 11.2±0.2°, 12.3±0.2°, 13.7±0.2°, 14.6±0.2°, 16.1±0.2°, 20.0±0.2°, 22.0±0.2°, 22.5±0.2° and 29.3±0.2°.
[0032] In some embodiments, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, as shown in Table 2:
[0033] Table 2
[0034] In some embodiments, the Form B of the 1,4-dioxane solvate of the compound of Formula II has an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG6 using Cu-Kα radiation.
[0035] In some embodiments, the differential scanning calorimetry (DSC) curve of Form B of the 1,4-dioxane solvate of the compound of Formula II has endothermic peaks at 107.2°C±3°C and 186.6°C±3°C.
[0036] In some embodiments, the differential scanning calorimetry curve of Form B of the 1,4-dioxane solvate of the compound of Formula II is shown in FIG7 .
[0037] In some embodiments, the thermogravimetric analysis (TGA) curve of Form B of the 1,4-dioxane solvate of the compound of Formula II shows a weight loss of 2.029% in the temperature range of 33°C±3°C to 150°C±3°C.
[0038] In some embodiments, the thermogravimetric analysis curve of Form B of the 1,4-dioxane solvate of the compound of Formula II is shown in FIG8 .
[0039] The present invention provides a crystalline form C of a compound of formula II, which has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.7±0.2°, 7.5±0.2°, 9.7±0.2° and 15.5±0.2°;
[0040] In some embodiments, the crystalline form C of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and further has diffraction peaks at one or more of the following positions: 11.3±0.2°, 12.3±0.2°, 14.4±0.2°, 14.7±0.2°, 17.2±0.2°, 20.5±0.2°, 21.8±0.2 and 29.5±0.2°.
[0041] In some embodiments, the crystalline form C of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.7±0.2°, 7.5±0.2°, 9.7±0.2°, 11.3±0.2°, 12.3±0.2°, 14.4±0.2°, 14.7±0.2°, 15.5±0.2°, 17.2±0.2°, 20.5±0.2°, 21.8±0.2 and 29.5±0.2°.
[0042] In some embodiments, the crystalline form C of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles having diffraction peaks as shown in Table 3:
[0043] Table 3
[0044] In some embodiments, the Form C of the compound of Formula II has an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 9 using Cu-Kα radiation.
[0045] In some embodiments, the differential scanning calorimetry (DSC) curve of Form C of the compound of Formula II has an endothermic peak at 196.9°C ± 3°C.
[0046] In some embodiments, the differential scanning calorimetry curve of Form C of the compound of Formula II is shown in FIG10 .
[0047] In some embodiments, the thermogravimetric analysis (TGA) curve of Form C of the compound of Formula II shows no weight loss within the temperature range of 30°C±3°C to 180°C±3°C.
[0048] In some embodiments, the thermogravimetric analysis curve of Form C of the compound of Formula II is shown in FIG11 .
[0049] In some embodiments, the crystalline form C of the compound of formula II is a crystalline form without a solvate.
[0050] In some embodiments, the crystalline Form C of the compound of Formula II is free of solvent.
[0051] The present invention provides a crystalline form D of a compound of formula II, which has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.9±0.2°, 8.1±0.2°, 10.6±0.2° and 14.9±0.2°;
[0052] In some embodiments, the crystalline form D of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and further has diffraction peaks at one or more of the following positions: 10.2±0.2°, 10.6±0.2°, 14.3±0.2°, 17.8±0.2°, 20.0±0.2° and 20.2±0.2°.
[0053] In some embodiments, the crystalline form D of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.9±0.2°, 8.1±0.2°, 10.2±0.2°, 10.6±0.2°, 14.3±0.2°, 14.9±0.2°, 17.8±0.2°, 20.0±0.2° and 20.2±0.2°.
[0054] In some embodiments, the crystalline form D of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles having diffraction peaks as shown in Table 4:
[0055] Table 4
[0056] In some embodiments, the crystalline form D of the compound of Formula II has an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 12 using Cu-Kα radiation.
[0057] In some embodiments, the differential scanning calorimetry (DSC) curve of Form D of the compound of Formula II has endothermic peaks at 178.3°C±3°C and 194.0°C±3°C.
[0058] In some embodiments, the differential scanning calorimetry curve of Form D of the compound of Formula II is shown in FIG13 .
[0059] In some embodiments, the thermogravimetric analysis (TGA) curve of Form D of the compound of Formula II shows a weight loss of 0.59% in the temperature range of 30°C±3°C to 101°C±3°C, and a weight loss of 0.81% in the temperature range of 140°C±3°C to 180°C±3°C.
[0060] In some embodiments, the thermogravimetric analysis curve of Form D of the compound of Formula II is shown in FIG14 .
[0061] In some embodiments, the crystalline form D of the compound of formula II is a crystalline form without a solvate.
[0062] In some embodiments, the crystalline form D of the compound of formula II is free of solvent.
[0063] The present invention provides a crystalline form E of a compound of formula II, which has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at diffraction peaks at 3.7±0.2°, 7.6±0.2°, 9.8±0.2° and 14.7±0.2°;
[0064] In some embodiments, the crystalline form E of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and further has diffraction peaks at one or more of the following positions: 11.2±0.2°, 15.6±0.2°, 17.4±0.2°, 19.8±0.2°, 20.3±0.2°, 21.9±0.2°, 29.5±0.2° and 19.0±0.2°.
[0065] In some embodiments, the crystalline form E of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.7±0.2°, 7.6±0.2°, 9.8±0.2°, 11.2±0.2°, 14.7±0.2°, 15.6±0.2°, 17.4±0.2°, 19.8±0.2°, 20.3±0.2°, 21.9±0.2° and 29.5±0.2°.
[0066] In some embodiments, the crystalline form E of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles having diffraction peaks as shown in Table 5:
[0067] Table 5
[0068] In some embodiments, the crystalline form E of the compound of Formula II has an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 15 using Cu-Kα radiation.
[0069] In some embodiments, the differential scanning calorimetry (DSC) curve of Form E of the compound of Formula II has an endothermic peak at 192.0°C±3°C.
[0070] In some embodiments, the differential scanning calorimetry curve of Form E of the compound of Formula II is shown in FIG16 .
[0071] In some embodiments, the thermogravimetric analysis (TGA) curve of Form E of the compound of Formula II shows no weight loss in the range of 30°C±3°C to 160°C±3°C.
[0072] In some embodiments, the thermogravimetric analysis curve of Form E of the compound of Formula II is shown in FIG17 .
[0073] In some embodiments, the crystalline form E of the compound of formula II is a solvate-free crystalline form.
[0074] In some embodiments, the crystalline Form E of the compound of Formula II is free of solvent.
[0075] The present invention provides a method for preparing a crystalline form of a compound of formula II, comprising the following steps:
[0076] (1) mixing the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I and a solvent to obtain a mixture;
[0077] (2) filtering the mixture and drying to obtain a crystalline form of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I;
[0078] Wherein, when the solvent is an alcohol solvent (such as methanol), the obtained product is the crystalline form A of the monohydrate of the compound of formula II;
[0079] When the solvent is 1,4-dioxane, the obtained product is the crystalline form B of the 1,4-dioxane solvate of the compound of formula II;
[0080] When the solvent is tetrahydrofuran, the crystalline form C of the compound of formula II is obtained.
[0081] In the preparation method, the mixing may be stirring suspension.
[0082] In the preparation method, the mixture obtained in step (1) can be a suspension.
[0083] In the preparation method, the drying is conventional in the art, such as drying under reduced pressure or drying under normal pressure.
[0084] In the preparation method, when the crystalline form A of the monohydrate of the compound of formula II is obtained, the mass volume ratio of the compound of formula II to the solvent can be 1:(1-100) g / ml, for example 1:30 g / mL.
[0085] In the preparation method, when the obtained crystal form A of the monohydrate of the compound of formula II is obtained, the mixing temperature can be 0-150° C., for example, the mixing temperature is 20-80° C., preferably heated to reflux.
[0086] In the preparation method, when the obtained crystal form A of the monohydrate of the compound of formula II is obtained, the mixing time is conventional in the art, for example, 2 hours.
[0087] In the preparation method, when the obtained crystal form A of the monohydrate of the compound of formula II is obtained, the filtration can be performed at room temperature, for example, the mixture is cooled to room temperature and then filtered.
[0088] In the preparation method, when the crystalline form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the mass volume ratio of the compound of formula II to the solvent can be 1:(10-50) g / ml, for example 1:20 g / ml.
[0089] In the preparation method, when the crystalline form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the mixing temperature can be room temperature, which is 20-30°C, for example, 25°C.
[0090] In the preparation method, when the crystalline form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the mixing time is conventional in the art, for example, 24 hours.
[0091] In the preparation method, when the crystalline form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the mixing operation is conventional in the art, such as stirring.
[0092] In the preparation method, when the obtained crystal form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the filtration can be performed at room temperature.
[0093] In the preparation method, when the crystalline form C of the compound of formula II is obtained, the mass volume ratio of the compound of formula II to the solvent can be 1:(5-20) g / ml, for example 1:10 g / ml.
[0094] In the preparation method, when the crystalline form C of the compound of formula II is obtained, the mixing temperature can be 45-55°C, for example, 25-50°C, preferably 50°C.
[0095] In the preparation method, when the crystalline form C of the compound of formula II is obtained, the mixing time is conventional in the art, for example, 48 hours.
[0096] In the preparation method, when the crystalline form C of the compound of formula II is obtained, the mixing operation is conventional in the art, such as stirring.
[0097] The present invention provides a method for preparing Form D of a compound of Formula II, comprising the following steps: heating Form C of the compound of Formula II or Form B of a 1,4-dioxane solvate of the compound of Formula II to 160° C. for 5 to 10 minutes to obtain (for example, after cooling) Form D of the compound of Formula II.
[0098] The present invention provides a method for preparing Form E of a compound of Formula II, comprising the following steps: heating Form B of a 1,4-dioxane solvate of the compound of Formula II or Form C of the compound of Formula II to 80-100° C. for 24-96 hours (e.g., 48 hours) to obtain Form E of the compound of Formula II.
[0099] The method for preparing the crystalline form of the compound of formula II may further comprise the following steps:
[0100] Step (1a): mixing the compound of formula I with solvent A to obtain a mixture A;
[0101] Step (1b): mixing 2-amino-2-(hydroxymethyl)-1,3-propanediol with solvent B to obtain mixture B;
[0102] Steps (1a) and (1b) are performed in no particular order;
[0103] Step (2): the mixture A and the mixture B are mixed, crystallized, filtered, and dried to obtain the compound of formula II.
[0104] In the step (1a), the solvent A is a conventional solvent in the art, preferably one or more of an alcohol solvent, an ester solvent, an ether solvent, a ketone solvent, a chlorinated hydrocarbon solvent, an aromatic hydrocarbon solvent, a nitrile solvent, an alkane solvent and a nitrogen-containing compound solvent, the alcohol solvent is, for example, methanol, ethanol or isopropanol, the ether solvent is, for example, methyl tert-butyl ether, isopropyl ether, tetrahydrofuran or 2-methyltetrahydrofuran, the nitrogen-containing compound solvent is, for example, N-methylpyrrolidone, the ester solvent is, for example, methyl formate, ethyl formate, ethyl acetate or ethyl acetate. Acid isopropyl ester, further preferably, the solvent A is methanol, ethanol, acetone, ethyl acetate, a mixed solution of n-heptane and ethyl acetate, a mixed solution of n-heptane and tetrahydrofuran, a mixed solution of methanol and water, a mixed solution of acetone and water, a mixed solution of ethanol and water, a mixed solution of tetrahydrofuran and water, "a mixed solution of methanol, water and dimethyl sulfoxide", "a mixed solution of 2-methyltetrahydrofuran, ethyl acetate and methanol", "a mixed solution of ethyl acetate, tetrahydrofuran and water" or "a mixed solution of ethyl acetate, 2-methyltetrahydrofuran and water".
[0105] Preferably, in step (1a), the solvent A is an alcohol solvent, for example, the solvent A is methanol.
[0106] In the step (1a), when the solvent A is a mixed solution of 2-methyltetrahydrofuran, ethyl acetate and methanol, the volume ratio of 2-methyltetrahydrofuran, ethyl acetate and methanol can be 5:5:2.
[0107] In the step (1a), the mass-to-volume ratio of the compound of formula I to the solution A is conventional in the art, preferably 10:(10-500) g / mL, for example 10:200 g / mL.
[0108] In the step (1a), the mixing temperature is conventional in the art, for example, 10 to 160°C, preferably 20 to 30°C.
[0109] In the step (1a), the mixture can be further filtered to obtain the mixture A
[0110] In the step (1b), the solvent B is a conventional solvent in the art, preferably one or more of water, an alcohol solvent and a sulfur-containing compound solvent. The alcohol solvent is, for example, ethanol or methanol, and the sulfur-containing compound solvent can be dimethyl sulfoxide.
[0111] Preferably, in step (1b), the solvent B is water.
[0112] In the step (1b), the mass ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol to the solvent B is conventional in the art, for example, 1:(1-260), preferably 3.2:800.
[0113] In the step (2), the mixing is conventional in the art, for example, the mixture B is dripped into the mixture A.
[0114] In the step (2), the crystallization temperature is a conventional temperature in the art, for example, 20 to 30°C.
[0115] In the step (2), the crystallization time is conventional in the art, generally until the compound of formula II no longer precipitates, for example, the mixing time is 1 to 24 hours, for example, 12 to 24 hours.
[0116] In the step (2), the filtration may include the steps of filtration, washing (for example, washing with the solution A and / or the solution B) and pH adjustment (for example, washing with water to a pH of 7 to 8).
[0117] In the step (2), the drying is conventional in the art, for example, vacuum drying at 45°C.
[0118] The present invention provides a pharmaceutical composition comprising a 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or a solvate thereof (a solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I), and a pharmaceutically acceptable carrier;
[0119] Preferably, the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or a solvate thereof is a single crystal of the monohydrate of the compound of formula II, the crystalline form A of the monohydrate of the compound of formula II, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II, the crystalline form C of the compound of formula II, the crystalline form D of the compound of formula II or the crystalline form E of the compound of formula II.
[0120] The present invention provides a use of the above-mentioned pharmaceutical composition or the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the above-mentioned compound of formula I or a solvate thereof (solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I) in the preparation of a medicament for preventing, treating and / or treating metabolic-related diseases;
[0121] Preferably, the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or a solvate thereof is a single crystal of the monohydrate of the compound of formula II, the crystalline form A of the monohydrate of the compound of formula II, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II, the crystalline form C of the compound of formula II, the crystalline form D of the compound of formula II or the crystalline form E of the compound of formula II.
[0122] In the application, the metabolic-related disease can be selected from any one of glucose intolerance, hyperglycemia, dyslipidemia, type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), hypertriglyceridemia, insulin resistance, impaired glucose tolerance (IGT), diabetic dyslipidemia, hyperlipidemia, arteriosclerosis, atherosclerosis, hypertension, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, cirrhosis and lethargy.
[0123] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.
[0124] The reagents and raw materials used in the present invention are commercially available.
[0125] The positive progress of the present invention is that the GLP-1R receptor agonist compound salt provided by the present invention has good stability, excellent solid properties, is stable under pressure, grinding and high humidity conditions, and has good pharmaceutical prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0126] FIG1 is an X-ray powder diffraction pattern of Form A of the monohydrate of the compound of Formula II.
[0127] FIG2 is a differential scanning calorimetry curve of Form A of the monohydrate of the compound of Formula II.
[0128] FIG3 is a thermogravimetric analysis curve of Form A of the monohydrate of the compound of Formula II.
[0129] FIG4 is a single crystal fitting X-ray powder diffraction pattern of the monohydrate of the compound of formula II.
[0130] FIG5 is a single crystal structure of the monohydrate of the compound of formula II.
[0131] FIG6 is an X-ray powder diffraction pattern of Form B of 1,4-dioxane solvate of the compound of Formula II.
[0132] FIG7 is a differential scanning calorimetry curve of Form B of 1,4-dioxane solvate of the compound of Formula II.
[0133] FIG8 is a thermogravimetric analysis curve of Form B of 1,4-dioxane solvate of the compound of Formula II.
[0134] FIG9 is an X-ray powder diffraction pattern of Form C of the compound of Formula II.
[0135] FIG10 is a differential scanning calorimetry curve of Form C of the compound of Formula II.
[0136] FIG11 is a thermogravimetric analysis curve of Form C of the compound of Formula II.
[0137] FIG12 is an X-ray powder diffraction pattern of Form D of the compound of Formula II.
[0138] FIG13 is a differential scanning calorimetry curve of Form D of the compound of Formula II.
[0139] FIG14 is a thermogravimetric analysis curve of Form D of the compound of Formula II.
[0140] FIG15 is an X-ray powder diffraction pattern of Form E of the compound of Formula II.
[0141] FIG16 is a differential scanning calorimetry curve of Form E of the compound of Formula II.
[0142] FIG17 is a thermogravimetric analysis curve of Form E of the compound of Formula II.
[0143] FIG18 is an X-ray powder diffraction pattern of Form I of the compound of Formula I.
[0144] FIG19 is an X-ray powder diffraction pattern of Form II of the compound of Formula I.
[0145] Figure 20 is an X-ray powder diffraction pattern of Form III of the compound of Formula I.
[0146] Figure 21 is the X-ray powder diffraction pattern of the tableting and grinding test of Form I of the compound of Formula I.
[0147] FIG22 is an X-ray powder diffraction pattern of the tableting and grinding test of Form II of the compound of Formula I.
[0148] FIG23 is an X-ray powder diffraction pattern of Form III of the compound of Formula I obtained by tableting and grinding.
[0149] FIG24 is an X-ray powder diffraction pattern of the crystalline form A of the monohydrate of the compound of formula II obtained by tableting.
[0150] FIG25 is an X-ray powder diffraction pattern of Form A of the monohydrate of the compound of Formula II obtained by tableting and grinding. DETAILED DESCRIPTION
[0151] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0152] The actual and adopted methods used in the examples of the present invention are all conventional reagents and conventional methods in the art. It should be clear to those skilled in the art that, hereinafter, unless otherwise specified, temperatures are expressed in degrees Celsius (° C.). The operating temperature is carried out at room temperature, which is 10-30° C.
[0153] Instruments and methods:
[0154] The reaction samples were analyzed using a variety of detection and analysis methods, including
[0155] (1) X-ray diffraction patterns were acquired using a Bruker D2 Phaser instrument. The instrument parameters were as follows:
[0156] (2)DSC
[0157] DSC curves were acquired using a TA Instruments DSC 250. Samples were accurately weighed into a sample pan, recorded, and then punctured in an aluminum crucible for testing. The temperature was increased from 25°C to a final temperature of 300°C at a rate of 10°C / min.
[0158] (3)TGA
[0159] TGA curves were acquired using a TA Instruments TGA 550. Samples were weighed into a sample pan and tested open-top, with the temperature rising from 40°C to 300°C at a heating rate of 10°C / min.
[0160] (4) HPLC, measurement parameters are shown in the following table:
[0161] Detection method:
[0162] Purity test: The sample to be tested was dissolved in methanol solution and the purity of the sample was tested by HPLC.
[0163] Hygroscopicity (DVS) test method: Sample hygroscopicity is measured using an SMS Intrinsic Plus. Samples are weighed into a sample pan and equilibrated at 25°C until the dm / dt ratio is less than 0.002%. The measurement is then performed using time-based mode. The humidity is stepped from 60% to 90% to 0% and then to 90% to 0% RH in 10% increments, with each humidity level maintained for 1 hour.
[0164] Grindability test: Place an appropriate amount of the crystalline compound to be tested into the mortar and grind for 2 minutes. After 5 minutes, detect its XRPD.
[0165] Compressibility test: The crystalline compounds to be tested were pressed into tablets at a pressure of 20 mPa and then the XRPD results were detected.
[0166] Solubility test:
[0167] About 10 mg of the crystalline compound was weighed and added to 3 ml of water, shaken, and maintained at 37° C. After 24 h, a sample was taken and tested by HPLC to calculate its solubility.
[0168] Example 1: (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate hydrochloride
[0169] Add methanol (20 ml) into the flask, and add acetyl chloride (1.53 g) dropwise. After the addition is complete, stir for 1 hour and set aside.
[0170] (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (10g) (i.e., compound of formula I, prepared by the same method as Example 3 of patent CN202110334388), was added with methanol (200ml) and stirred at a temperature of 20-30°C. The methanol solution was slowly added dropwise to the methanol solution of the compound of formula I. After the addition was completed, the mixture was stirred for 1h, and water (100ml) was added dropwise. After stirring for 3h, the mixture was filtered. The filter cake was washed twice with methanol / water (50ml*2, 2:1). The filter cake was vacuum dried at 45°C to constant weight to obtain 9.1g of the product. 1H NMR (400MHz) CD3OD)9.62-9.72(1H,m),8.12(1H,d),7.99-8.01(1H,dd),7.72-7.73(1H,d),7.4 5-7.48 (1H, m), 7.32-7.34 (1H, dd), 7.22-7.26 (3H, m), 7.09-7.12 (1H, td), 6.85-6. 86(1H,dd),5.19-5.20(2H,d),4.55-4.60(1H,q),4.09-4.22(2H,ABq),3.94-3.96( 1H, d), 3.77-3.89 (2H, m), 3.06-3.20 (4H, m), 2.31-2.48 (5H, m), 2.22-2.29 (1H, m).
[0171] HPLC purity: 94.74%.
[0172] Example 2: Sodium (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate
[0173] To (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (2 g) (prepared by the same method as in Example 3 of patent CN202110334388), dimethyl sulfoxide (1 ml) was added and the temperature was controlled at 20-30 ° C with stirring. Sodium hydroxide solution (3.75 ml, 1 mol / L) was added dropwise. Under stirring, acetone (20 ml) was added dropwise. After stirring for 5 h, the mixture was filtered, and the filter cake was quickly washed twice with acetone. Then, it was transferred to a flask and dried under reduced pressure to obtain an off-white solid (1.5 g). 1H NMR(400MHz CD3OD)8.13(1H,m),8.09-8.10(1H,dd),7.74-7.76(1H,d),7.41-7.44(1H,ddt),7.31-7.32(1H,dd),7.23-7.26(3H,m),7.15-7.11(1H,m),6.85 -6.87(1H,m),5.19-5.20(2H,d),4.55-4.60(1H,m),4.04-4.21(2H,ABq ), 3.77-3.88(2H,m), 3.63(2H,s), 2.85-2.95(3H,m), 2.72-2.78(2H,m). HPLC purity: 99.90%.
[0174] Example 3: 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate
[0175] 10 g of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (prepared by the same method as Example 3 of patent CN202110334388) was added to methanol (200 ml) and stirred at 20-30°C to dissolve the mixture. The mixture was then filtered. Tris(hydroxymethyl)aminomethane (3.2 g) was dissolved in 800 g of water and slowly added dropwise to the reaction mixture. The mixture was stirred at 20-30°C to precipitate a solid. The mixture was stirred for 12-24 hours. The mixture was filtered and the filter cake was washed twice with methanol / water (500 ml*2, 2:1) until the pH was 7-8. The filter cake was vacuum dried at 45°C to constant weight to obtain 11.0 g of the product, which is the compound of formula II. 1H NMR (400 MHz) CD3OD)8.21(1H,d),7.96-7.97(1H,dd),7.94-7.95(1H,d),7.50-7.61(1H,td),7.25-7.29(2H,m ), 7.20-7.22(2H, m), 6.96-7.02(1H, dd), 6.94-6.96(1H, t), 5.12(1H, m), 4.95(2H, s), 4.85-4.8 9 (2H, m), 4.73-4.74 (1H, m), 4.63-4.70 (1H, m), 4.47-4.48 (1H, m), 3.67-4.46 (2H, ABq), 3.67 (6H, s), 2.96-3.02 (3H, m), 2.78-2.88 (1H, m), 2.48-2.58 (1H, m) 2.20-2.28 (2H, m) 1.75-1.80 (4H, m). HPLC purity: 99.95%.
[0176] Example 3-1: 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate
[0177] 10 g of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (prepared by the same method as Example 3 of patent CN202110334388) was added to tetrahydrofuran (400 ml) and stirred at 20-30° C. to dissolve the mixture, followed by filtration. Tris(hydroxymethyl)aminomethane (2.1 g) was dissolved in 150 g of water and slowly added dropwise to the reaction mixture. The mixture was stirred at 20-30° C. to precipitate a solid and stirred for 10-16 hours. The mixture was filtered and the filter cake was washed twice with tetrahydrofuran / water (80 ml * 2, 3:1) until the pH was 7-8. The filter cake was vacuum dried at 45° C. to constant weight to obtain 11.4 g of the product, i.e., the compound of formula II.
[0178] Example 3-2: 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate
[0179] To 10 g of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (prepared by the same method as Example 3 of patent CN202110334388), add N-methylpyrrolidone (20 ml), control the temperature at 120-150 ° C, stir and dissolve, and filter; dissolve trishydroxymethylaminomethane (4.2 g) in 50 g of water, slowly add dropwise to the above reaction solution, control the temperature at 20-30 ° C, stir to precipitate solid, and stir for 10-16 hours; filter, wash the filter cake twice with ethyl acetate (30 ml * 2), and wash with water until the pH is 7-8. The filter cake is vacuum dried at 45 ° C to constant weight to obtain a product weighing 9.1 g, i.e., compound II.
[0180] Example 3-3: 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate
[0181] To 10 g of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (prepared by the same method as in Example 3 of patent CN202110334388) was added 2-methyltetrahydrofuran (50 ml), ethyl acetate (50 ml), and methanol (20 ml), stirred at 20-30°C to dissolve the mixture, and filtered. Tris(hydroxymethyl)aminomethane (2.1 g) was dissolved in 30 g of water and slowly added dropwise to the reaction solution. The mixture was stirred at 20-30°C to precipitate a solid and stirred for 2-3 hours. The mixture was filtered and the filter cake was washed twice with ethyl acetate (10 ml * 2) and then with water until the pH was 7-8. The filter cake was vacuum dried at 45°C to constant weight to obtain a product weighing 11.9 g, i.e., compound II.
[0182] Example 3-4: 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate
[0183] 10 g of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (prepared by the same method as Example 3 of patent CN202110334388) was added to ethanol (300 ml) and stirred at 78°C to dissolve the mixture. The mixture was then filtered. Tris(hydroxymethyl)aminomethane (3.2 g) was dissolved in ethanol (100 ml) and slowly added dropwise to the reaction mixture. The mixture was stirred at 20-30°C to precipitate a solid. The mixture was stirred for approximately 8 hours. The mixture was filtered and the filter cake was washed twice with ethanol (50 ml x 2). The filter cake was vacuum dried at 45°C to constant weight to obtain 12.0 g of the product, which is the compound of formula II.
[0184] Crystal transfer process
[0185] Example 4: Form A of 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Compound of Formula II) Monohydrate
[0186] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (1 g) prepared in Example 3 was added to methanol (30 ml), stirred, heated under reflux for 2 h, naturally cooled to room temperature, and stirred for 2 h. The solid was filtered to obtain a solid, which was dried under reduced pressure to constant weight to obtain 0.80 g of the product, which is Form A of the monohydrate of 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound of Formula II).
[0187] The XRPD pattern analysis data of the crystalline form A of the monohydrate of the compound of formula II are shown in Table 1.
[0188] Table 1
[0189] The characterization data of the crystalline form A of the monohydrate of the compound of formula II are as follows:
[0190] The obtained monohydrate crystalline form A of the compound of formula II is a single crystal of the monohydrate of the compound of formula II. Its fitted XRPD pattern is shown in FIG4 , its single crystal structure is shown in FIG5 , and its main crystal parameter data are as follows:
[0191] Example 5: Form B of 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Compound of Formula II) 1,4-dioxane Solvate
[0192] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (2 g) prepared in Example 3 was added to 1,4-dioxane (40 ml), stirred at room temperature for 24 h, filtered to obtain a solid, and dried under reduced pressure to constant weight to obtain 1.90 g of the product (i.e., Form B of the 1,4-dioxane solvate of the compound of Formula II, wherein the molar ratio of the compound of Formula II to 1,4-dioxane is 1:0.5). 1H NMR (400 MHz) CD3OD)8.22(1H,s),7.95-7.97(1H,dd),7.60-7.62(1H,d),7.51-7.53(1H,t),7.27-2.29(2H,m ), 7.15-7.21(1H, m), 7.01-7.05(1H, d), 6.93-6.97(1H, t), 5.27-5.30(1H, m), 4.63-4.75(2H, m) , 4.47-4.49 (1H, m), 3.85-4.03 (2H, ABq), 3.67-3.68 (10H, m), 3.32-3.34 (4H, m), 2.94-3.06 (3H, m), 2.79-2.83 (1H, m), 2.52-2.57 (1H, m), 2.22-2.34 (1H, m), 1.73-1.82 (4H, m) HPLC purity: 99.99%.
[0193] The XRPD pattern analysis data of Form B of the 1,4-dioxane solvate of the compound of Formula II are shown in Table 2.
[0194] Table 2
[0195] The characterization data of Form B of the 1,4-dioxane solvate of the compound of Formula II are as follows:
[0196] Example 6: Form C of 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Compound of Formula II)
[0197] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (2 g) prepared in Example 3 was added to tetrahydrofuran (20 ml) and stirred at 25-50° C. for 48 h. The solid was filtered and dried under reduced pressure to constant weight to obtain 2.10 g of the product (Form C of the compound of Formula II). 1H NMR (400 MHz) DMSO-d6)8.19(1H,d),7.79-7.81(1H,dd),7.51-7.60(2H,m),7.36-7.39(1H,dd),7.16-7.21(2H,m),7. 07-7.09 (1H, dd), 6.92-6.96 (1H, td), 5.15 (2H, s), 5.06-5.15 (1H, m), 4.73-4.79 (2H, dd), 4.60-4.65 (1 H, d) 4.47-4.52 (1H, m), 4.34-4.39 (1H, m), 3.75-3.96 (2H, ABq), 3.55-3.61 (m), 3.38 (6H, s), 2.96-2.99 (1H, d), 2.85-2.90 (2H, m), 2.66-2.75 (1H, m), 2.38-2.45 (2H, m), 2.10-2.22 (2H, m), 1.54-1.71 (4H, m). The XRPD pattern analysis data of Form C of the compound of Formula II are shown in Table 3.
[0198] Table 3
[0199] The characterization data of Form C of the compound of Formula II are shown in the following table:
[0200] Example 7: Form D of 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Compound of Formula II)
[0201] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (0.50 g, Form B of the 1,4-dioxane solvate of the compound of Formula II or Form C of the compound of Formula II) prepared in Example 5 or 6 was heated to 160° C. for 5-10 minutes and cooled to obtain 0.46 g of a solid (i.e., Form D of the compound of Formula II). 1H NMR (400 MHz) CD3OD)8.22(1H,s),7.95-7.97(1H,dd),7.60-7.62(1H,d),7.52-7.56(1H,t),7.27-7.30(2H,m),7. 21-7.24(1H, dd), 7.15-7.20(1H, td), 7.02-7.04(1H, dd), 6.93-6.97(1H, td), 5.25-5.32(1H, qd), 5 .14(1H, s), 4.71-4.75(1H, dd), 4.62-4.67(1H, m), 4.45-4.50(1H, m), 3.90-4.03(2H, ABq), 3.66(6H , s), 2.95-3.06 (4H, m), 2.77-2.85 (1H, m), 2.50-2.59 (1H, m), 2.22-2.34 (1H, m), 1.71-1.81 (4H, m). HPLC purity: 99.9%.
[0202] The XRPD pattern analysis data of Form D of the compound of Formula II are shown in Table 4.
[0203] Table 4
[0204] The characterization data of Form D of the compound of Formula II are shown in the following table:
[0205] Example 8: Form E of 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Compound of Formula II)
[0206] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (0.20 g, Form B of the 1,4-dioxane solvate of the compound of Formula II or Form C of the compound of Formula II) prepared in Example 5 or 6 was heated to 80-100° C. and dried for 48 h to obtain 0.18 g of a solid (i.e., Form E of the compound of Formula II). 1H NMR (400 MHz) CD3OD)8.22(1H,s),7.95-7.97(1H,dd),7.60-7.62(1H,d),7.51-7.55(1H,t),7.27-7.30(2H,m),7 .21-7.23(1H,m),7.15-7.20(1H,td),7.01-7.04(1H,dd),6.93-6.97(1H,td),5.25-5.32(1H,qd),5 .14(1H, s), 4.71-4.75(1H, dd), 4.62-4.67(1H, m), 4.45-4.50(1H, m), 3.90-4.03(2H, ABq), 3.64(6H , s), 2.94-3.06 (4H, m), 2.77-2.85 (1H, m), 2.50-2.59 (1H, m), 2.22-2.34 (1H, m), 1.75-1.81 (4H, m). HPLC Purity: 99.9%
[0207] The XRPD pattern analysis data of Form E of the compound of Formula II are shown in Table 5.
[0208] Table 5
[0209] The characterization data of the crystalline form E of the compound of formula II are shown in the following table:
[0210] Example 9: Form A of 2-amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetane-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Compound of Formula II) Monohydrate
[0211] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (0.20 g) prepared in Example 5 or 6 was added to n-heptane (50 ml), stirred, heated to 50° C., and refluxed with stirring for 96 h. The mixture was naturally cooled to room temperature and stirred for 2 h. The solid was filtered and dried under reduced pressure to constant weight to obtain 0.18 g of the product, which was confirmed to be Form A of the monohydrate of the compound of Formula II with an HPLC purity of 99.8%.
[0212] Example 10: 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (Form A of the Monohydrate of the Compound of Formula II)
[0213] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (0.20 g) prepared in Example 8 was placed under 25° C. / 90% RH for 4-5 days and weighed 0.21 g. It was confirmed to be Form A of the monohydrate of the compound of Formula II with an HPLC purity of 99.9%.
[0214] Example 11: (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Formula I Compound Form I)
[0215] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg) prepared in Example 3 was added to acetone (1.2 ml) and heated to 50°C for dissolution. The mixture was then cooled to approximately 25°C and slowly added dropwise with water (0.5 ml). The mixture was stirred at room temperature for 24 hours, filtered to obtain a solid, and dried under reduced pressure to constant weight to obtain 150 mg of the compound of Formula I, Form I. XRPD: See Figure 18. DSC: 144.32-154.74°C, endothermic.
[0216] The XRPD diffraction pattern analysis data of Form I of the compound of Formula I are shown in Table 6.
[0217] Table 6
[0218] Example 12: (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Formula I Compound Form II)
[0219] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg) prepared in Example 3 was added to tetrahydrofuran (1 ml) and n-heptane (2 ml). The mixture was heated to 50°C and stirred for 24 hours. After cooling to room temperature, the solid was filtered and dried under reduced pressure to constant weight to obtain 180 mg of the compound of Formula I, Form II. XRPD: See Figure 19. DSC: 111.96-129.32°C, endothermic.
[0220] The XRPD diffraction pattern analysis data of Form II of the compound of Formula I are shown in Table 7.
[0221] Table 7
[0222] Example 13: (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Formula I Compound Form III)
[0223] 2-Amino-2-(hydroxymethyl)-1,3-propanediol, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg) prepared in Example 3 was added to methanol (1 ml) and water (1 ml). The mixture was stirred at 25°C for 24 hours. After cooling to room temperature, the solid was filtered and dried under reduced pressure to constant weight to obtain 163 mg of the compound of Formula I, Form III. XRPD: See Figure 20. DSC: 101.13-121.83°C, endothermic, and 136.87-147.61°C, endothermic.
[0224] The obtained crystalline form III of the compound of formula I is a crystalline form of an anhydrate of the compound of formula I.
[0225] The XRPD diffraction pattern analysis data of Form III of the compound of Formula I are shown in Table 8.
[0226] Table 8
[0227] Effect test 1:
[0228] The purity and hygroscopicity of (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate hydrochloride (the hydrochloride salt of the compound of Formula I) obtained in Example 1, (S)-2-((4-(2-((4-chloro-2-fluorobenzyl)oxy)phenyl)piperidin-1-yl)methyl)-1-(oxetan-2-aminomethyl)-1H-benzo[d]imidazole-6-carboxylate sodium salt (the sodium salt of the compound of Formula I) obtained in Example 2, and the crystalline form A of the monohydrate of the compound of Formula II obtained in Example 4 were tested.
[0229] The properties of the three different salts are compared in Table 9.
[0230] Table 9
[0231] Effect Test 2: Comparison of Crystal Forms of 2-Amino-2-(Hydroxymethyl)-1,3-Propanediol Salt of Formula I
[0232] Comparative Examples 4 to 8 obtained the crystalline form A of the monohydrate of the compound of formula II, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II, the crystalline form C of the compound of formula II, the crystalline form D of the compound of formula II and the crystalline form E of the compound of formula II.
[0233] X-ray powder diffraction patterns of the various crystalline forms indicate that Form A of the monohydrate of the compound of Formula II exhibits high crystallinity. Furthermore, during preparation, Form B of the 1,4-dioxane solvate of the compound of Formula II and Form C of the compound of Formula II were found to be unstable, prone to form transformation during preparation, and exhibited poor reproducibility. The preparation of Form D and Form E of the compound of Formula II involves heating, and the corresponding crystalline forms are obtained at high temperatures, making them unsuitable for scale-up production (see Table 10).
[0234] Table 10
[0235] Effect Test 3
[0236] The grindability, compressibility, hygroscopicity and solubility of the crystalline forms I, II and III of the compound of formula I obtained in Examples 11-13 and the crystalline form A of the monohydrate of the compound of formula II obtained in Example 4 were tested.
[0237] The DVS test data of the crystalline form I of the compound represented by formula I obtained in Example 11 are shown in Table 11.
[0238] Table 11
[0239] The DVS test data of the crystalline form A of the monohydrate of the compound of formula II obtained in Example 4 are shown in Table 12.
[0240] Table 12
[0241] The comparative data of compound stability are shown in Table 13.
[0242] Table 13
[0243] Remark:
[0244] a The preparation method is the same as Example 3 of patent CN202110334388.
[0245] b In the purity test, the sample is placed in an oven, the temperature is set according to the table, and the purity is tested after the specified time.
[0246] c The results were obtained by placing the sample at 80°C for 30 days.
[0247] As can be seen from the above table, the compound of formula I has poor thermal stability and will degrade when heated or at room temperature. It also has poor processability and obvious degradation during grinding and tableting.
[0248] Among them, the crystalline forms I, II, and III of the compound of formula I have poor processability. As shown in Figures 21, 22, and 23, compared with the crystalline forms I, II, and III of the compound of formula I, the crystalline forms I, II, and III after tableting, the crystalline forms I, II, and III after grinding for 5 minutes, and the crystalline forms I, II, and III after grinding for 2 minutes all have varying degrees of reduced crystallinity. In contrast, as shown in Figures 24 and 25, the crystalline form A of the monohydrate of the compound of formula II, after the first tableting at 20 MPa, the second tableting at 20 MPa, and the tableting at 40 MPa, remains substantially stable in crystallinity after grinding for 1 minute, 3 minutes, and 5 minutes with the crystalline form A, it can be seen that the crystalline form A of the monohydrate of the compound of formula II has good processability. In addition, the crystalline form A of the monohydrate of the compound of formula II is stable, has good experimental reproducibility, has good hygroscopicity and solubility, and has broad prospects for pharmaceutical use.
[0249] Test Example 4: Pharmacokinetic Evaluation in Rats
[0250] Rats were used as test animals, and the drug concentration in plasma at different times after oral administration of the test substance was tested. The pharmacokinetic behavior of the compound of the present invention in rats was studied, and its drug metabolism characteristics were evaluated. Three rats of similar body weight were selected for each group of examples, and a single oral dose of 10 mg / kg was administered. Blood was collected from the animals at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration. The compound content in plasma was detected by LC-MS / MS analysis, and the quantitative limit of the method was 20 ng / mL. The concentration data in plasma were statistically analyzed using the metabolic kinetic data analysis software WinNonlin 7.0, and the pharmacokinetic parameters were calculated using the non-compartmental model (NCA) method.
[0251] Experimental drugs: Crystalline form A of the monohydrate of the compound of formula II obtained in Example 4 and the compound of formula I (free acid).
[0252] Drug configuration:
[0253] The test samples were prepared to a final concentration (based on the content of the compound of formula I) of 1.0 mg / mL for oral administration. The preparation solvent was 0.5% CMC Na aqueous solution. After preparation, a milky white uniform suspension was obtained.
[0254] Administration: Rats were fasted overnight (12 hours) and then orally administered with a dose of 10 mg / kg.
[0255] Procedure: Rats were orally administered with the drug, and blood was collected from the tail vein before and 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h after administration. The blood was placed in a heparinized sample tube, and the plasma was separated by centrifugation at 3500 rpm for 10 min at 4°C. The plasma was stored at -20°C and the rats were fed 2 h after administration.
[0256] Determination of the test compound in rat plasma following oral administration: Plasma samples were thawed at room temperature and spiked with 300 μL of internal standard (terfenadine 200 ng / mL, acetonitrile). The samples were vortexed for 1 minute and centrifuged at 4°C, 15,400 rpm, for 10 minutes. The supernatant was diluted 20-fold with 80% acetonitrile water and injected into the sample for LC / MS / MS analysis.
[0257] As shown in the table above, the monohydrate form A of the compound of formula II of the present invention has significantly better oral absorption than the compound of formula I (free acid).
Claims
1. A 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of a compound of formula I or a solvate thereof; 2. The 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I according to claim 1 or a solvate thereof, characterized in that: It meets one or more of the following conditions: (1) The 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I is a compound of formula II, (2) In the solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I, the solvent is water or 1,4-dioxane; in the solvate of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I, the molar ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I to the solvent is preferably 1:(1-0.5), for example, the molar ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I to the water is 1:1, and for another example, the molar ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I to the 1,4-dioxane is 1:0.
5.
3. A crystalline form of a compound of formula II or a solvate thereof, characterized in that: It is the crystalline form A of the monohydrate of the compound of formula II, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II, the crystalline form C of the compound of formula II, the crystalline form D of the compound of formula II or the crystalline form E of the compound of formula II; Wherein, the structure of the monohydrate of the compound of formula II is: The structure of the 1,4-dioxane solvate of the compound of formula II is: The structure of the compound of formula II is: The crystalline form A of the monohydrate of the compound of formula II has diffraction peaks at 4.1±0.2°, 8.2±0.2°, 10.7±0.2°, 12.3±0.2° and 20.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form B of the 1,4-dioxane solvate of the compound of formula II has diffraction peaks at 3.4±0.2°, 7.4±0.2°, 11.2±0.2° and 14.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form C of the compound of formula II has diffraction peaks at 3.7±0.2°, 7.5±0.2°, 9.7±0.2° and 15.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form D of the compound of formula II has diffraction peaks at 3.9±0.2°, 8.1±0.2°, 10.6±0.2° and 14.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form E of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, with diffraction peaks at 3.7±0.2°, 7.6±0.2°, 9.8±0.2° and 14.7±0.2°.
4. The crystalline form of the compound of formula II or its solvate as claimed in claim 3, characterized in that: The crystalline form of the compound of formula II satisfies one or more of the following conditions: (1) Form A of the monohydrate of the compound of formula II, which has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 14.1±0.2°, 14.9±0.2°, 20.5±0.2° and 21.8±0.2°; Preferably, the crystalline form A of the monohydrate of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 4.1±0.2°, 8.2±0.2°, 10.7±0.2°, 12.3±0.2°, 14.1±0.2°, 14.9±0.2°, 20.5±0.2° and 21.8±0.2°; (2) The crystalline form B of the 1,4-dioxane solvate of the compound of formula II has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 8.2±0.2°, 12.3±0.2°, 13.7±0.2°, 16.1±0.2°, 20.0±0.2°, 22.0±0.2°, 22.5±0.2° and 29.3±0.2°; Preferably, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II uses Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles at 3.4±0.2°, 7.4±0.2°, 8.2±0.2°, 11.2±0.2°, 12.3±0.2°, 13.7±0.2°, 14.6±0.2°, There are diffraction peaks at 16.1±0.2°, 20.0±0.2°, 22.0±0.2°, 22.5±0.2°, and 29.3±0.2°; (3) The X-ray powder diffraction pattern of the crystalline form C of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles also has diffraction peaks at one or more of the following positions: 11.3±0.2°, 12.3±0.2°, 14.4±0.2°, 14.7±0.2°, 17.2±0.2°, 20.5±0.2°, 21.8±0.2 and 29.5±0.2°; Preferably, the crystalline form C of the compound of formula II has diffraction peaks at 3.7±0.2°, 7.5±0.2°, 9.7±0.2°, 11.3±0.2°, 12.3±0.2°, 14.4±0.2°, 14.7±0.2°, 15.5±0.2°, 17.2±0.2°, 20.5±0.2°, 21.8±0.2 and 29.5±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (4) The X-ray powder diffraction pattern of the crystalline form D of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles also has diffraction peaks at one or more of the following positions: 10.2±0.2°, 10.6±0.2°, 14.3±0.2°, 17.8±0.2°, 20.0±0.2° and 20.2±0.2°; Preferably, the crystalline form D of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.9±0.2°, 8.1±0.2°, 10.2±0.2°, 10.6±0.2°, 14.3±0.2°, 14.9±0.2°, 17.8±0.2°, 20.0±0.2° and 20.2±0.2°; and (5) The crystalline form E of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 11.2±0.2°, 15.6±0.2°, 17.4±0.2°, 19.8±0.2°, 20.3±0.2°, 21.9±0.2°, 29.5±0.2° and 19.0±0.2°; Preferably, the crystalline form E of the compound of formula II has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 3.7±0.2°, 7.6±0.2°, 9.8±0.2°, 11.2±0.2°, 14.7±0.2°, 15.6±0.2°, 17.4±0.2°, 19.8±0.2°, 20.3±0.2°, 21.9±0.2° and 29.5±0.2°.
5. The crystalline form of the compound of formula II or its solvate according to claim 4, characterized in that: The crystalline form of the compound of formula II satisfies one or more of the following conditions: (1) The X-ray powder diffraction pattern of the monohydrate of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 1: Table 1 Preferably, the crystalline form A of the monohydrate of the compound of formula II uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG1 ; (2) The differential scanning calorimetry curve of the crystalline form A of the monohydrate of the compound of formula II has endothermic peaks at 129.98±3°C and 196.25±3°C; Preferably, the differential scanning calorimetry curve of the crystalline form A of the monohydrate of the compound of formula II is as shown in FIG2 ; (3) The thermogravimetric analysis curve of the crystalline form A of the monohydrate of the compound of formula II shows a weight loss of 2.468% in the temperature range of 30°C±3°C to 135°C±3°C; Preferably, the thermogravimetric analysis curve of the crystalline form A of the monohydrate of the compound of formula II is shown in FIG3 ; (4) The X-ray powder diffraction pattern of the 1,4-dioxane solvate of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 2: Table 2 Preferably, the crystalline form B of the 1,4-dioxane solvate of the compound of formula II uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG6 ; (5) The differential scanning calorimetry curve of the crystalline form B of the 1,4-dioxane solvate of the compound of formula II has endothermic peaks at 107.2°C±3°C and 186.6°C±3°C; Preferably, the differential scanning calorimetry curve of the crystalline form B of the 1,4-dioxane solvate of the compound of formula II is shown in FIG7 ; (6) The thermogravimetric analysis curve of the crystalline form B of the 1,4-dioxane solvate of the compound of formula II shows a weight loss of 2.029% in the temperature range of 33°C±3°C to 150°C±3°C; Preferably, the thermogravimetric analysis curve of Form B of the 1,4-dioxane solvate of the compound of Formula II is shown in FIG8 ; (7) The X-ray powder diffraction pattern of the crystalline form C of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 3: Table 3 Preferably, the crystal form C of the compound of formula II uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in Figure 9; (8) The differential scanning calorimetry curve of the crystalline form C of the compound of formula II has an endothermic peak at 196.9°C ± 3°C; Preferably, the differential scanning calorimetry curve of the crystalline form C of the compound of formula II is shown in FIG10 ; (9) The thermogravimetric analysis curve of Form C of the compound of Formula II shows no weight loss in the temperature range of 30°C±3°C to 180°C±3°C; Preferably, the thermogravimetric analysis curve of the crystal form C of the compound of formula II is shown in FIG11 ; (10) The crystalline form C of the compound of formula II is a crystalline form without a solvate; (11) The X-ray powder diffraction pattern of the crystalline form D of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 4: Table 4 Preferably, the crystal form D of the compound of formula II uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG12 ; (12) The differential scanning calorimetry curve of the crystalline form D of the compound of formula II has endothermic peaks at 178.3°C±3°C and 194.0°C±3°C; Preferably, the differential scanning calorimetry curve of the crystalline form D of the compound of formula II is shown in FIG13 ; (13) The thermogravimetric analysis curve of Form D of the compound of Formula II shows a weight loss of 0.59% in the temperature range of 30°C±3°C to 101°C±3°C, and a weight loss of 0.81% in the temperature range of 140°C±3°C to 180°C±3°C; Preferably, the thermogravimetric analysis curve of the crystal form D of the compound of formula II is shown in FIG14 ; (14) The crystalline form D of the compound of formula II is a crystalline form without a solvate; (15) The X-ray powder diffraction pattern of the crystalline form E of the compound of formula II using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 5: Table 5 Preferably, the crystalline form E of the compound of formula II uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG15 ; (16) The differential scanning calorimetry curve of the crystalline form E of the compound of formula II has an endothermic peak at 192.0°C ± 3°C; Preferably, the differential scanning calorimetry curve of the crystalline form E of the compound of formula II is shown in FIG16 ; (17) The thermogravimetric analysis curve of Form E of the compound of Formula II shows no weight loss in the range of 30°C±3°C to 160°C±3°C; Preferably, the thermogravimetric analysis curve of Form E of the compound of Formula II is shown in FIG17 ; and (18) The crystalline form E of the compound of formula II is a crystalline form without a solvate.
6. A single crystal of a monohydrate of a compound of formula II, characterized in that: It has the following unit cell parameters: space group P212121; α=90°, β=90°, γ=90°, The number of asymmetric units in the unit cell is Z = 4, and the crystal density is 1.379 mg / m 3 ; Wherein, the structure of the monohydrate of the compound of formula II is: Preferably, the single crystal of the monohydrate of the compound of formula II is an orthorhombic system.
7. A method for preparing a crystalline form of a compound of formula II or a solvate thereof as claimed in any one of claims 3 to 5, characterized in that: It contains the following steps: (1) mixing a 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of a compound of formula (I) as claimed in claim 1 or 2 with a solvent to obtain a mixture; (2) filtering the mixture and drying it to obtain a crystalline form of the compound of formula II or a solvate thereof; in, When the solvent is an alcohol solvent, the obtained product is the crystalline form A of the monohydrate of the compound of formula II; When the solvent is 1,4-dioxane, the obtained product is the crystalline form B of the 1,4-dioxane solvate of the compound of formula II; When the solvent is tetrahydrofuran, the obtained compound is Form C of Formula II; Preferably, the preparation method meets one or more of the following conditions: (1) In the preparation method, the alcohol solvent is methanol; (2) In the preparation method, the mixing is stirring suspension; (3) In the preparation method, the mixture obtained in step (1) is a suspension; (4) In the preparation method, the drying is performed by drying under reduced pressure or drying under normal pressure; (5) In the preparation method, when the crystalline form A of the monohydrate of the compound of formula II is obtained, the mass volume ratio of the compound of formula II to the solvent is 1: (1-100) g / ml, for example 1: 30 g / mL; (6) In the preparation method, when the obtained crystal form A of the monohydrate of the compound of formula II is obtained, the mixing temperature is 0-150°C, for example, the mixing temperature is 20-80°C, preferably heated to reflux; (7) In the preparation method, when the obtained product is the crystalline form A of the monohydrate of the compound of formula II, the filtration is performed at room temperature, for example, the mixture is cooled to room temperature and then filtered; (8) In the preparation method, when the obtained crystalline form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the mass volume ratio of the compound of formula II to the solvent is 1: (10-50) g / ml, for example 1: 20 g / ml; (9) In the preparation method, when the obtained crystalline form B of the 1,4-dioxane solvate of the compound of formula II is obtained, the mixing temperature is room temperature, and the room temperature is 20 to 30° C., for example, 25° C.; (10) In the preparation method, when the obtained product is the crystalline form B of the 1,4-dioxane solvate of the compound of formula II, the mixing operation is stirring; (11) In the preparation method, when the obtained product is Form B of 1,4-dioxane solvate of the compound of Formula II, the filtration is performed at room temperature; (12) In the preparation method, when the crystalline form C of the compound of formula II is obtained, the mass ratio of the compound of formula II and the solvent is The volume ratio is 1: (5-20) g / ml, for example 1: 10 g / ml; (13) In the preparation method, when the obtained crystal form C of the compound of formula II is obtained, the mixing temperature is 45-55°C, for example 25-50°C, preferably 50°C; and (14) In the preparation method, when the obtained crystal form C of the compound of formula II is obtained, the mixing operation is stirring.
8. The preparation method according to claim 7, characterized in that: The preparation method further comprises the following steps: Step (1a): mixing a compound of formula I with a solvent A to obtain a mixture A; Step (1b): 2-amino-2-(hydroxymethyl)-1,3-propanediol is mixed with solvent B to obtain mixture B; Steps (1a) and (1b) are performed in no particular order; Step (2): mixing the mixture A and the mixture B, crystallizing, filtering, and drying to obtain the compound of formula II; Preferably, the preparation method meets one or more of the following conditions: (1) In step (1a), the solvent A is one or more of an alcohol solvent, an ester solvent, an ether solvent, a ketone solvent, a chlorinated hydrocarbon solvent, an aromatic hydrocarbon solvent, a nitrile solvent, an alkane solvent and a nitrogen-containing compound solvent. The alcohol solvent is, for example, methanol, ethanol or isopropanol; the ether solvent is, for example, methyl tert-butyl ether, isopropyl ether, tetrahydrofuran or 2-methyltetrahydrofuran; the nitrogen-containing compound solvent is, for example, N-methylpyrrolidone; and the ester solvent is, for example, methyl formate, ethyl formate, ethyl acetate or isopropyl acetate. , further preferably, the solvent A is methanol, ethanol, acetone, ethyl acetate, a mixed solution of n-heptane and ethyl acetate, a mixed solution of n-heptane and tetrahydrofuran, a mixed solution of methanol and water, a mixed solution of acetone and water, a mixed solution of ethanol and water, a mixed solution of tetrahydrofuran and water, "a mixed solution of methanol, water and dimethyl sulfoxide", "a mixed solution of 2-methyltetrahydrofuran, ethyl acetate and methanol", "a mixed solution of ethyl acetate, tetrahydrofuran and water" or "a mixed solution of ethyl acetate, 2-methyltetrahydrofuran and water"; Furthermore, in the step (1a), the solvent A is an alcohol solvent, for example, the solvent A is methanol; (2) In step (1a), the mass volume ratio of the compound of formula I to the solution A is 10:(10-500) g / mL, for example, 10:200 g / mL; (3) In step (1a), the mixing temperature is 10 to 160° C., preferably 20 to 30° C.; (4) In the step (1a), the mixing is further filtered to obtain the mixture A; (5) In step (1b), the solvent B is one or more of water, an alcohol solvent and a sulfur-containing compound solvent, the alcohol solvent is, for example, ethanol or methanol, and the sulfur-containing compound solvent is dimethyl sulfoxide; Preferably, in step (1b), the solvent B is water; (6) In the step (1b), the mass ratio of the 2-amino-2-(hydroxymethyl)-1,3-propanediol to the solvent B is 1:(1-260), preferably 3.2:800; (7) In step (2), the mixing is performed by dripping the mixture B into the mixture A; (8) In step (2), the crystallization temperature is 20 to 30° C.; (9) In step (2), the filtration comprises the steps of filtration, washing and pH adjustment; (10) In step (2), the drying is performed at 45° C. under vacuum; and (11) In step (1a), when the solvent A is a mixed solution of 2-methyltetrahydrofuran, ethyl acetate and methanol, 2- The volume ratio of methyltetrahydrofuran, ethyl acetate and methanol is 5:5:
2.
9. A method for preparing the crystalline form D of the compound of formula II as claimed in any one of claims 3 to 5, characterized in that: The method comprises the following steps: heating the crystalline form C of the compound of formula II as claimed in any one of claims 3 to 5 or the crystalline form B of the 1,4-dioxane solvate of the compound of formula II as claimed in any one of claims 3 to 5 to 160° C. for 5 to 10 minutes to obtain the crystalline form D of the compound of formula II.
10. A method for preparing the crystalline form E of the compound of formula II as claimed in any one of claims 3 to 5, characterized in that: The method comprises the following steps: heating the crystalline form B of the 1,4-dioxane solvate of the compound of formula II or the crystalline form C of the compound of formula II as claimed in any one of claims 3 to 5 to 80 to 100° C. for 24 to 96 hours to obtain the crystalline form E of the compound of formula II.
11. A pharmaceutical composition, characterized in that It comprises a 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of a compound of formula I according to any one of claims 1 or 2 or a solvate thereof, and a pharmaceutically acceptable carrier; Preferably, the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or a solvate thereof is a single crystal of the monohydrate of the compound of formula II as claimed in claim 6 or a crystalline form of the compound of formula II or a solvate thereof as claimed in any one of claims 3 to 5.
12. Use of the pharmaceutical composition according to claim 11 or the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or a solvate thereof according to any one of claims 1 or 2 in the preparation of a medicament for preventing, controlling and / or treating metabolic-related diseases; Preferably, the 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or a solvate thereof is a single crystal of a monohydrate of the compound of formula II as claimed in claim 6 or a crystalline form of the compound of formula II or a solvate thereof as claimed in any one of claims 3 to 5; In the application, the metabolism-related disease can be selected from any one of glucose intolerance, hyperglycemia, dyslipidemia, type 1 diabetes, type 2 diabetes, hypertriglyceridemia, insulin resistance, impaired glucose tolerance, diabetic dyslipidemia, hyperlipidemia, arteriosclerosis, atherosclerosis, hypertension, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver fibrosis, cirrhosis and lethargy.
